Results 21 to 30 of about 25,780 (241)

Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

Drug Delivery, 2021
Topotecan is potent anti-cancer drug approved for various malignancies but hematopoietic toxicities undermine its wider application and use of its most effective dose. This study aims to improve these limitations through inhalation-delivery.
Philip J. Kuehl, Christin M. Yingling, Devon Dubose, Michael Burke, David A. Revelli, Wenshu Chen, Wendy W. Dye, Steven A. Belinsky, Mathewos Tessema   +8 more
doaj   +1 more source

Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study

British Journal of Ophthalmology, 2021
Background Current melphalan-based intravitreal regimens for retinoblastoma (RB) vitreous seeds cause retinal toxicity. We assessed the efficacy and toxicity of topotecan monotherapy compared with melphalan in our rabbit model and patient cohort. Methods
Carley M. Bogan, Jessica V. Kaczmarek, J. Pierce, Sheau-Chiann Chen, K. Boyd, M. Calcutt, T. M. Bridges, C. Lindsley, Jennifer B Nadelmann, Albert Liao, Terry Hsieh, D. Abramson, J. Francis, D. Friedman, A. Richmond, Anthony B. Daniels   +15 more
semanticscholar   +1 more source

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

The Lancet Oncology, 2020
BACKGROUND Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line ...
N. Baize, I. Monnet, L. Greillier, M. Geier, H. Léna, H. Janicot, A. Vergnenègre, J. Crequit, R. Lamy, J. Auliac, J. Letreut, H. Le Caer, R. Gervais, É. Dansin, A. Madroszyk, P. Renault, G. Legarff, L. Falchero, H. Bérard, R. Schott, P. Saulnier, C. Chouaid   +21 more
semanticscholar   +1 more source

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo

Molecules, 2022
The use of cancer chemotherapy sensitizers is a promising approach to induce the effect of clinically used anticancer treatments. One of the interesting targets is Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), a DNA-repair enzyme, that may prevent the action ...
Irina A. Chernyshova, Aleksandra L. Zakharenko, Nikolay N. Kurochkin, Nadezhda S. Dyrkheeva, Tatyana E. Kornienko, Nelly A. Popova, Valeriy P. Nikolin, Ekaterina S. Ilina, Timofey D. Zharkov, Maxim S. Kupryushkin, Vladimir E. Oslovsky, Mikhail S. Drenichev, Olga I. Lavrik   +12 more
doaj   +1 more source

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Advances in Therapy, 2020
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications.
L. Hart, R. Ferrarotto, Z. Andrić, J. Beck, J. Subramanian, D. Radosavljevic, B. Zarić, W. Hanna, R. Aljumaily, T. Owonikoko, D. Verhoeven, Jie Xiao, S. Morris, J. Antal, M. Hussein   +14 more
semanticscholar   +1 more source

Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells

Arthritis & Rheumatology, 2021
To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli‐1 and topoisomerase, on lupus nephritis in (NZB × NZW)F1 (NZBWF1) mice, and to examine the effects of CPT and TPT on inflammatory ...
Xuan Wang, James C. Oates, K. Helke, G. Gilkeson, Xian K. Zhang   +4 more
semanticscholar   +1 more source

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Frontiers in Oncology, 2023
ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi, Nuojin Guo, Zeming Zhao, Ligang Liu, Tianyi Ni, Jinye Zhang, Yingjie Lu   +6 more
doaj   +1 more source

Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling [PDF]

, 2008
A mathematical multi-cell model for the in vitro kinetics of the anti-cancer agent topotecan (TPT) following administration into a culture medium containing a population of human breast cancer cells (MCF-7 cell line) is described.
Chappell, M. J. (Michael J.), Godfrey, Keith, Godfrey, K. R., Evans, Neil D., Cheung, S. Y. Amy, Errington, Rachel J., Cheung, S. Y. A., Errington, Rachel Jane, Smith, Paul J., Evans, N. D., Smith, Paul James, Chappell, M. J.   +11 more
core   +1 more source

Evaluation of The Effect of Topotecan, Carvacrol, Epigallocatechin Gallate and Their Combination on Apoptotic Process in Neuroblastoma and Astrocyte Cells

, 2023
Neuroblastoma is a sympathetic nervous system cancer. Neuroblastoma most commonly affects children under five years of age and is the most common solid tumor in childhood. Topotecan is a topoisomerase 1 inhibitor.
Akıncı, Melek, Oltulu, Çağatay, Bakar, Elvan, Akinci, Melek   +3 more
core   +2 more sources

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER [PDF]

Journal of IMAB, 2010
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent ...
Deyan Davidov
doaj   +1 more source